H Zach1,2, U Walter3, I Liepelt-Scarfone4, W Maetzler5. 1. Universitätsklinik für Neurologie, Medizinische Universität Wien, Wien, Österreich. 2. Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Radboud University Medical Centre, Nijmegen, Niederlande. 3. Klinik und Poliklinik für Neurologie, Universitätsmedizin Rostock, Rostock, Deutschland. 4. Hertie Institut für klinische Hirnforschung, Universität Tübingen und Deutsches Zentrum für Neurodegenerative Erkrankungen, Tübingen, Deutschland. 5. Klinik für Neurologie, Universitätsklinikum Schleswig-Holstein, Arnold-Heller-Straße 3, 24105, Kiel, Deutschland. w.maetzler@neurologie.uni-kiel.de.
Abstract
BACKGROUND: Recently, the Movement Disorder Society (MDS) published an adaptation of the previous United Kingdom Brain Bank Society (UKBBS) criteria for the diagnosis of idiopathic Parkinson's disease (iPD). OBJECTIVES: This article presents the changes in the current clinical diagnostic criteria for IPD. Furthermore, the new MDS criteria for prodromal iPD are discussed. RESULTS: The recently introduced MDS criteria for the clinical diagnosis of iPD include useful novel features (e.g. postural instability is no longer listed as a cardinal symptom, familiar history of iPD and intake of neuroleptics at the first visit no longer lead to exclusion of the diagnosis) and red flags do not lead to exclusion of the diagnosis; however, they must be counterbalanced by the presence of supportive criteria for iPD. The criteria for identification of persons in the prodromal stage are currently established only for scientific investigations. CONCLUSION: The new MDS criteria for the diagnostics of iPD should help to improve the sensitivity and specificity.
BACKGROUND: Recently, the Movement Disorder Society (MDS) published an adaptation of the previous United Kingdom Brain Bank Society (UKBBS) criteria for the diagnosis of idiopathic Parkinson's disease (iPD). OBJECTIVES: This article presents the changes in the current clinical diagnostic criteria for IPD. Furthermore, the new MDS criteria for prodromal iPD are discussed. RESULTS: The recently introduced MDS criteria for the clinical diagnosis of iPD include useful novel features (e.g. postural instability is no longer listed as a cardinal symptom, familiar history of iPD and intake of neuroleptics at the first visit no longer lead to exclusion of the diagnosis) and red flags do not lead to exclusion of the diagnosis; however, they must be counterbalanced by the presence of supportive criteria for iPD. The criteria for identification of persons in the prodromal stage are currently established only for scientific investigations. CONCLUSION: The new MDS criteria for the diagnostics of iPD should help to improve the sensitivity and specificity.
Entities:
Keywords:
Bradykinesia; Movement disorders; Neuroleptics; Postural stability; Tremor
Authors: Daniela Berg; Ronald B Postuma; Charles H Adler; Bastiaan R Bloem; Piu Chan; Bruno Dubois; Thomas Gasser; Christopher G Goetz; Glenda Halliday; Lawrence Joseph; Anthony E Lang; Inga Liepelt-Scarfone; Irene Litvan; Kenneth Marek; José Obeso; Wolfgang Oertel; C Warren Olanow; Werner Poewe; Matthew Stern; Günther Deuschl Journal: Mov Disord Date: 2015-10 Impact factor: 10.338
Authors: Martin Köllensperger; Felix Geser; Klaus Seppi; Michaela Stampfer-Kountchev; Martin Sawires; Christoph Scherfler; Sylvia Boesch; Joerg Mueller; Vasiliki Koukouni; Niall Quinn; Maria Teresa Pellecchia; Paolo Barone; Nicole Schimke; Richard Dodel; Wolfgang Oertel; Erik Dupont; Karen Østergaard; Christine Daniels; Günther Deuschl; Tanya Gurevich; Nir Giladi; Miguel Coelho; Cristina Sampaio; Christer Nilsson; Håkan Widner; Francesca Del Sorbo; Alberto Albanese; Adriana Cardozo; Eduardo Tolosa; Michael Abele; Thomas Klockgether; Christoph Kamm; Thomas Gasser; Ruth Djaldetti; Carlo Colosimo; Giuseppe Meco; Anette Schrag; Werner Poewe; Gregor K Wenning Journal: Mov Disord Date: 2008-06-15 Impact factor: 10.338
Authors: Philipp Mahlknecht; Arno Gasperi; Peter Willeit; Stefan Kiechl; Heike Stockner; Johann Willeit; Gregorio Rungger; Martin Sawires; Michael Nocker; Verena Rastner; Katherina J Mair; Anna Hotter; Werner Poewe; Klaus Seppi Journal: Mov Disord Date: 2016-06-06 Impact factor: 10.338
Authors: Stefanie Lerche; Inga Liepelt-Scarfone; Guido Alves; Paolo Barone; Stefanie Behnke; Yoav Ben-Shlomo; Henk Berendse; David Burn; Richard Dodel; Donald Grosset; Sebastian Heinzel; Michele Hu; Meike Kasten; Rejko Krüger; Walter Maetzler; Marcello Moccia; Brit Mollenhauer; Wolfgang Oertel; Benjamin Roeben; Ulrike Sünkel; Uwe Walter; Karin Wirdefeldt; Daniela Berg Journal: Neuroepidemiology Date: 2015-11-03 Impact factor: 3.282
Authors: Christopher G Goetz; Barbara C Tilley; Stephanie R Shaftman; Glenn T Stebbins; Stanley Fahn; Pablo Martinez-Martin; Werner Poewe; Cristina Sampaio; Matthew B Stern; Richard Dodel; Bruno Dubois; Robert Holloway; Joseph Jankovic; Jaime Kulisevsky; Anthony E Lang; Andrew Lees; Sue Leurgans; Peter A LeWitt; David Nyenhuis; C Warren Olanow; Olivier Rascol; Anette Schrag; Jeanne A Teresi; Jacobus J van Hilten; Nancy LaPelle Journal: Mov Disord Date: 2008-11-15 Impact factor: 10.338
Authors: Ayse Ulusoy; Raffaella Rusconi; Blanca I Pérez-Revuelta; Ruth E Musgrove; Michael Helwig; Bettina Winzen-Reichert; Donato A Di Monte Journal: EMBO Mol Med Date: 2013-05-23 Impact factor: 12.137
Authors: Michael Lawton; Meike Kasten; Margaret T May; Brit Mollenhauer; Martina Schaumburg; Inga Liepelt-Scarfone; Walter Maetzler; Eva-Juliane Vollstedt; Michele T M Hu; Daniela Berg; Yoav Ben-Shlomo Journal: Mov Disord Date: 2016-02-10 Impact factor: 10.338